Vivital Biomed Ltd.

 

Vvital is dedicated to improving the long-term stability of Transcatheter Mitral Valve Repair (TMVRr).

Based on the invention of Prof. Aram Smolinsky, Vvital developed the VLR system providing Valve Leaflet Repair with an Annuloplasty effect in one procedure.  

 

This unique combination, up to now present only in surgical procedures, is a true game changer in  Transcatheter MR treatment. 

Trendlines logo.png

Investor

The Trendlines Group

Management

 Ed Rieflin 
Chairman 

Mr. Ed Rieflin has 35 years as an executive in cardiovascular devices.  Most recently, Ed served for 19 years at Thoratec Corporation, St. Jude Medical and Abbott Laboratories as Senior Vice President - Heart Failure Sales.  Thoratec was acquired by St. Jude Medical in 2015 for $3.4B, and St. Jude Medical was acquired by Abbott in 2017 for $25B. Ed holds a B.S. degree in economics from Cornell University.

  • LinkedIn
Ed Rieflin4.jpeg

Nir Golan
CEO, Co-founder

Mr. Nir Golan has 25 years’ experience in executive business management in leading global public high-tech companies and start-ups; extensive experience in business development, M&A, start-up establishment, technology, global sales, and marketing; B.A., economics, Tel Aviv University; Executive MBA, The Hebrew University of Jerusalem.

  • LinkedIn

Prof. Aram Smolinsky, M.D. 

CMO, Co-founder & Inventor 

Prof. Aram Smolinsky has 35  years’ clinical and academic experience as cardiac surgeon and researcher; former director of Open-Heart Surgery Department, Sheba Medical Center; performed >7,000 open-heart procedures; leader in mitral valve repair operations in Israel; M.D. and Associate Professor of Surgery, Sackler School of Medicine, Tel Aviv University.

  • LinkedIn